Status:
COMPLETED
Dynamic Optical Coherence Tomography(D-OCT) Aging Study: A Preliminary Evaluation of Structural Differences Between Young and Aged Skin, Cellulite and Atrophic Acne Scars in Female Caucasian Subjects With Fitzpatrick Skin Types I-III Utilizing Non-invasive in Vivo D-OCT.
Lead Sponsor:
Allergan
Conditions:
Skin Care
Eligibility:
FEMALE
18-75 years
Brief Summary
This single-center clinical study is being conducted over the course of 2 weeks to conduct an exploratory pilot study as a preliminary evaluation of D-OCT's ability to measure skin changes from aging....
Eligibility Criteria
Inclusion
- Female Caucasian subjects with Fitzpatrick skin types I-III that meet one of the criteria listed below:
- Ages 18-30 years old without acne scars on the face with or without visible cellulite on posterior thigh, or
- Ages 55-75 years old without acne scars on the face with or without visible cellulite on posterior thigh, or
- Ages 18-75 years old with atrophic acne scars
- Subject has completed an appropriately administered informed consent process which includes signing the IRB approved consent form.
- Good general health and free of any disease state or physical condition (e.g. psoriasis, rosacea, scars, tattoos etc.) which, in the investigator's opinion, might impair evaluations of the test sites or expose the subject to an unacceptable risk by study participation.
- Willingness to remove all makeup on the day of the visit. Makeup may be applied after the study visit has been completed.
- Willingness to cleanse their face and remove all face makeup at each scheduled clinic visit. No other topical products should be applied to the face until the study visit has been completed.
- i. For cellulite subgroup, willingness to have thigh cleansed at each scheduled clinic visit.
- Willingness to have investigator exams, skin instrumentation measurements, and digital photos performed on the face and/or thigh (for cellulite subgroup).
- Women of childbearing potential must not be pregnant at the time of the study.
Exclusion
- Has any condition that, in the opinion of the investigator, would make it unsafe for the subject to participate in the study or interfere with their clinical assessments (including conditions that require the concurrent use of anticoagulants, bleeding coagulopathies, photosensitivity diseases).
- Individuals with active symptoms of allergy, cold sore or warts, active psoriasis or eczema, rosacea, sunburn, open wounds, neurotic excoriations, tattoos, or other skin conditions in the test areas that would interfere with the assessments of this study.
- Individuals who are pregnant.
- Uncontrolled disease such as diabetes, hypertension, hyper or hypo-thyroidism, active hepatitis, immune deficiency, or autoimmune.
- Individuals who have a pre-existing or dormant dermatologic condition (e.g. history of severe psoriasis, atopic dermatitis, rosacea, skin cancer, etc.)
- Individuals who have routinely used any of the following topical products, prescription products, or had any of the listed treatments/procedures within the listed time frame prior to study entry or will use during study:
- Any product that the investigator deems that could affect the study objectives. These include products that address skin imperfections. This does not include a basic cleanser, moisturizer and sunscreen.(time frame 2 weeks)
- Chemical peel, microdermabrasion, dermaplaning, or microneedling (time frame 3 months)
- Retin-A®, Retin-A Micro®, Renova®, Avita®, Tazorac®, Avage® or Differin® or other similar prescription drugs (time frame 3 months)
- Cosmetic injections (filler and/or toxins, i.e. Juvederm, Radiesse, Botox, etc.), non-ablative laser or fractional laser resurfacing (time frame 12 months)
- Accutane® or other oral retinoid, Ablative procedures (i.e. laser, chemical) (time frame 12 months)
- Individuals who have any planned surgeries or procedures during the study.
- Individuals who participated in a facial usage study within the last 30 days, or who are currently participating on another usage study.
- Individuals currently on or planning to participate on any type of research study at another facility or a doctor's office during this study.
Key Trial Info
Start Date :
December 7 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 30 2019
Estimated Enrollment :
99 Patients enrolled
Trial Details
Trial ID
NCT03767400
Start Date
December 7 2018
End Date
July 30 2019
Last Update
October 31 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Skinmedica Clinical Research and Innovation Center
Irvine, California, United States, 92612